Asterias Biotherapeutics, Inc. (AST)

[tradetrak]

Listened to the conference call. It seems that we're in good financial shape for at least a year now. The most interesting thing to me though was that, while efficacy date on the dose escalated cohorts isn't anticipated until 2016, Pedro made a point of saying that they ARE tracking efficacy in the lower dose because the switch to the cervical area means a much smaller injury site. The results from this cohort is expected in the second half 2015.
Anybody else tune in? Thoughts?